Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

Biogen BIIB announced that the FDA and EMA have accepted its regulatory filings seeking label expansion for a higher dose of ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful ... doing nothing to quell debate about its commercial prospects. The latest study – called CORAL ...

Chris Viehbacher spoke out about the uncertain policy environment for life sciences companies, though he didn't single ...

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...

The company and Biogen continue to work to grow Zurzuvae in PPD as well. Sage slashes half its workforce in rejig targeting Zulresso commercial team Sage’s stock closed Friday at a price of $5. ...

Biogen CEO Christopher Viehbacher wrote that his company’s experience selling nervous system drugs would “enable more streamlined operations and efficient commercial execution” around ...

Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its ...

Biogen Inc. announced that the FDA has accepted ... the potential of our commercial business and pipeline programs, including SPINRAZA; and risks and uncertainties associated with drug development ...

Citi analyst Geoff Meacham lowered the firm’s price target on Biogen (BIIB) to $160 from $190 and keeps a Neutral rating on the shares. Ahead ...